David A. Kass

Active 1985–2025

276
Papers
63,802
Citations
136
h-index
269
i10-index

Citations

Citations per year for David A. Kass1971: 4 citations1979: 1 citations1981: 2 citations1987: 1 citations1988: 5 citations1989: 13 citations1990: 8 citations1991: 6 citations1992: 9 citations1993: 11 citations1994: 13 citations1995: 21 citations1996: 51 citations1997: 44 citations1998: 82 citations1999: 88 citations2000: 168 citations2001: 182 citations2002: 255 citations2003: 330 citations2004: 400 citations2005: 542 citations2006: 546 citations2007: 556 citations2008: 553 citations2009: 649 citations2010: 578 citations2011: 642 citations2012: 612 citations2013: 562 citations2014: 560 citations2015: 512 citations2016: 453 citations2017: 441 citations2018: 419 citations2019: 1,410 citations2020: 1,621 citations2021: 1,628 citations2022: 1,202 citations2023: 899 citations2024: 1,454 citations2025: 697 citations2026: 16 citations1972–1978: no citations, so these years are not shown1980: no citations, so this year is not shown1982–1986: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 6,183 citing papers, 30.2% of this breakdownUnited Kingdom: 1,445 citing papers, 7% of this breakdownChina: 1,407 citing papers, 6.9% of this breakdownGermany: 1,216 citing papers, 5.9% of this breakdownItaly: 1,089 citing papers, 5.3% of this breakdownNetherlands: 857 citing papers, 4.2% of this breakdownCanada: 814 citing papers, 4% of this breakdownFrance: 738 citing papers, 3.6% of this breakdownJapan: 630 citing papers, 3.1% of this breakdownAustralia: 594 citing papers, 2.9% of this breakdownBelgium: 364 citing papers, 1.8% of this breakdownSpain: 364 citing papers, 1.8% of this breakdown
0%30.2%Other 23.3%

Fields

  • Medicine72.1%
  • Biochemistry, Genetics and Molecular Biology19.5%
  • Engineering2.2%
  • Neuroscience2.1%
  • Immunology and Microbiology1.5%
  • Nursing0.5%
  • Other2.1%

Topics

  • Cardiovascular Function and Risk Factors8.6%
  • Cardiac electrophysiology and arrhythmias4%
  • Heart Failure Treatment and Management3.9%
  • Cardiac pacing and defibrillation studies3.6%
  • Cardiac Fibrosis and Remodeling3%
  • Cardiovascular Health and Disease Prevention2.9%
  • Other74%

Coauthors

All papers

Open in search
  1. Nitrosative stress drives heart failure with preserved ejection fraction

    Authors: , , , , , , , , , , , , , , , , , , , - Nature, Nat. 2019 cited by 944

  2. Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction

    Authors: , , , , , , , , , , , , - Circulation 2023 cited by 284

  3. Mechanisms, Pathophysiology, and Therapy of Arterial Stiffness

    Authors: , , - Arteriosclerosis Thrombosis and Vascular Biology 2005 cited by 1,844

  4. Cellular and molecular pathobiology of heart failure with preserved ejection fraction

    Authors: , - Nature Reviews Cardiology 2021 cited by 398

  5. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction

    Authors: , , , , , , - Circulation 2016 cited by 980

  6. NAD + Repletion Reverses Heart Failure With Preserved Ejection Fraction

    Authors: , , , , , , , , , , , , , - Circulation Research 2021 cited by 222

  7. Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction

    Authors: , , , , , , , , , , , , - Circulation 2020 cited by 282

  8. Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure

    Authors: , , , , , , , , , , , - New England Journal of Medicine 2004 cited by 5,817

  9. Research Priorities for Heart Failure With Preserved Ejection Fraction

    Authors: , , , , , , , , , , , , , , , , , - Circulation 2020 cited by 417

  10. Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis

    Authors: , , , , , , , , , , , , , , , , , , , , - JACC Heart Failure 2020 cited by 285

  11. Parkin‐independent mitophagy requires Drp1 and maintains the integrity of mammalian heart and brain

    Authors: , , , , , , , , , , , , , - The EMBO Journal 2014 cited by 417

  12. Age- and Gender-Related Ventricular-Vascular Stiffening

    Authors: , , , , - Circulation 2005 cited by 802

  13. Role of Oxidative Stress in Cardiac Hypertrophy and Remodeling

    Authors: , - Hypertension 2006 cited by 763

  14. Impaired Chronotropic and Vasodilator Reserves Limit Exercise Capacity in Patients With Heart Failure and a Preserved Ejection Fraction

    Authors: , , , , , , - Circulation 2006 cited by 690

  15. Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David A. Kass, You-Tang Shen, Stephen F. Vatner, David J. Morgans - Science 2011 cited by 602

  16. Measurement of cardiac function using pressure–volume conductance catheter technique in mice and rats

    Authors: , , , , - Nature Protocols 2008 cited by 723

  17. Heart Failure With Preserved Ejection Fraction

    Authors: , - Circulation Research 2014 cited by 497

  18. Combined Ventricular Systolic and Arterial Stiffening in Patients With Heart Failure and Preserved Ejection Fraction

    Authors: , , , - Circulation 2003 cited by 928

  19. Pulmonary Capillary Wedge Pressure Augments Right Ventricular Pulsatile Loading

    Authors: , , , , , , , , , , , - Circulation 2011 cited by 471

  20. Right Ventricular Dysfunction in Systemic Sclerosis–Associated Pulmonary Arterial Hypertension

    Authors: , , , , , , , , , , , , , , , , , - Circulation Heart Failure 2013 cited by 291

  21. Cardiac fibroblasts mediate IL-17A–driven inflammatory dilated cardiomyopathy

    Authors: , , , , , , , , , , , , - The Journal of Experimental Medicine 2014 cited by 182

  22. Noninvasive single-beat determination of left ventricular end-systolic elastance in humans

    Authors: , , , , , , , - Journal of the American College of Cardiology 2001 cited by 642

  23. Right Ventricular Myofilament Functional Differences in Humans With Systemic Sclerosis–Associated Versus Idiopathic Pulmonary Arterial Hypertension

    Authors: , , , , , , , , , , , , , - Circulation 2018 cited by 144

  24. Pulmonary Effective Arterial Elastance as a Measure of Right Ventricular Afterload and Its Prognostic Value in Pulmonary Hypertension Due to Left Heart Disease

    Authors: , , , , , , , , , , , , , , - Circulation Heart Failure 2018 cited by 133